Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO7567132 + atezolizumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
RO7567132 + atezolizumab is an investigational combination therapy being evaluated for the treatment of advanced or metastatic solid tumors. RO7567132 is a first-in-class, bi-specific stromal immunomodulatory agonist designed to enable and enhance the efficacy of cancer immunotherapies, while atezolizumab is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor. The combination aims to modulate the tumor microenvironment and boost anti-tumor immune responses in patients who have limited treatment options due to resistance or intolerance to standard therapies. The regimen is currently under investigation in Phase 1 clinical trials for safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in adults with advanced solid tumors[3][5][9].
- Brand names
- atezolizumab (Tecentriq)
- Other names
- RO7567132 + atezolizumab
02
Targets
FAP (Fibroblast activation protein alpha)TNFR (TNF receptor family)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on RO7567132 + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO7567132 + atezolizumab.